The Class Profile Shared Across All Three Compounds
Semaglutide, tirzepatide, and retatrutide are all GLP-1 receptor agonists that produce a recognisable class-level adverse event profile. The dominant signal across published Phase 2 and Phase 3 trials of all three compounds is gastrointestinal: nausea, vomiting, diarrhoea, and constipation account for the majority of reported events. The underlying mechanism is the GLP-1-mediated delay of gastric emptying combined with central appetite suppression — both target effects of the class, manifesting as observable adverse events.
This article compares the class-level GI side-effect profile reported in the major published trials of each compound. The comparison is across separate trials with different populations, dose schedules, and endpoints — not a controlled head-to-head study — so the magnitudes are not directly equivalent, but the patterns are consistent and worth understanding for protocol design.
RetaLABS supplies research-grade semaglutide, tirzepatide, and retatrutide as reference compounds for laboratory and pre-clinical research. The data below is drawn from the published clinical trials of each compound as a reference for the class profile researchers should expect.
Gastrointestinal Events — the Dominant Class Effect
Across the three compounds, the most-reported adverse events at the highest research-relevant doses cluster within the same GI category. The table summarises the four most-reported GI events at each compound's maximum trial dose:
| Event | Semaglutide 2.4mg (STEP 1, 68w) | Tirzepatide 15mg (SURMOUNT-1, 72w) | Retatrutide 12mg (Phase 2, 48w) |
|---|---|---|---|
| Nausea | ~44% | ~29% | ~42% |
| Vomiting | ~24% | ~13% | ~20% |
| Diarrhoea | ~30% | ~23% | ~18% |
| Constipation | ~24% | ~17% | ~14% |
Several patterns emerge from this cross-trial comparison:
- Nausea is the leading reported GI event for all three compounds. The proportion of subjects reporting nausea at any point during the trial is similar across the class.
- Vomiting rates are correlated with nausea rates but lower in magnitude — most nausea episodes do not progress to vomiting.
- Diarrhoea and constipation rates vary more between compounds. The variation likely reflects differences in receptor subtype targeting (the GIP component in tirzepatide and the additional glucagon component in retatrutide engage downstream gut-motility pathways differently from GLP-1 alone).
- Tirzepatide shows numerically lower GI event rates than the other two compounds at maximum dose. One mechanistic hypothesis is that GIP receptor co-activation modulates GLP-1-induced nausea pathways centrally; this remains an active research question.
Trial population, dose-escalation schedule, and trial duration all affect reported AE rates, so the magnitudes above should be interpreted as research benchmarks rather than direct ranks. The shared GI profile is the actionable observation for protocol design.
Less Common Adverse Events
Beyond the dominant GI cluster, the published trials report a smaller number of less-frequent events that recur across the class:
| Event | Typical rate (max dose) | Onset pattern |
|---|---|---|
| Decreased appetite | Majority of subjects across all three compounds | Early onset, sustained throughout protocol — this is the intended pharmacological effect rather than an off-target adverse event |
| Injection site reactions | ~5–10% | Local, typically transient |
| Headache | ~5–15% | Variable; may correlate with reduced caloric intake |
| Fatigue | ~5–10% | Often associated with the caloric deficit produced by appetite suppression |
| Gallbladder-related events | <5% (cholelithiasis, cholecystitis) | Associated with rapid weight loss; not unique to GLP-1 agonists |
Pancreatitis was a concern raised early in the GLP-1 receptor agonist class development but has not been confirmed at elevated rate in subsequent large trials. Thyroid C-cell tumours were reported in rodent toxicology studies of semaglutide and tirzepatide but have not been observed at elevated rates in human trials. No cases of pancreatitis or thyroid tumours were reported in the Phase 2 retatrutide trial.
Dose Dependence and Titration as AE Management
GI adverse events in all three compounds are dose-dependent: rates rise with each dose-escalation step and peak during titration. By the time research subjects reach maintenance dose (with appropriate escalation), GI event rates typically decline from peak titration levels. This pattern has shaped the standard dose-escalation protocols across the class.
The three compounds use similar 4–8 week initial titration windows in their published research protocols:
- Semaglutide: 4-week dose-doubling steps from 0.25mg → 0.5mg → 1.0mg → 1.7mg → 2.4mg (STEP 1 protocol).
- Tirzepatide: 4-week steps from 2.5mg → 5mg → 7.5mg → 10mg → 12.5mg → 15mg (SURMOUNT-1 protocol).
- Retatrutide: 2-week steps in early titration (1mg → 2mg → 4mg → 6mg → 8mg → 12mg), reaching maximum dose by approximately week 12 (Phase 2 protocol).
Research protocols that compress titration windows produce higher peak GI event rates. Protocols that extend titration spread the AE burden over more weeks but typically reduce peak severity. This trade-off is one of the design variables in research protocols studying dose-response relationships.
For full dosing protocols of each compound, see the semaglutide dosing protocol, tirzepatide dosing protocol, and retatrutide dosing protocol.
Discontinuation Data — How Often AEs End the Protocol
Published trial discontinuation rates due to adverse events provide a research-protocol-relevant signal for tolerability:
| Trial | AE-driven discontinuation at max dose | Notes |
|---|---|---|
| STEP 1 (semaglutide 2.4mg, 68w) | ~4.5% | Most discontinuations were in the early titration window |
| SURMOUNT-1 (tirzepatide 15mg, 72w) | ~4.3% | Similar distribution; tirzepatide discontinuations slightly skewed to lower-dose arms |
| Retatrutide Phase 2 (12mg, 48w) | ~6.4% | Higher than the other two; consistent with retatrutide's compressed titration schedule |
For research protocols where retention is a primary endpoint, tirzepatide has the lowest published discontinuation rate among the three at maximum dose. For protocols where peak efficacy at the cost of higher AE burden is acceptable, retatrutide's profile is the most aggressive. Semaglutide sits in the middle on both metrics.
Each protocol decision is research-question-specific. RetaLABS supplies all three compounds research-grade so that researchers can select the compound matching their experimental design rather than the supply-channel constraint.